This supports the usefulness of inflammation (I) biomarkers (such as plasma GFAP) to establish a more accurate diagnosis scheme in the clinic but also provides novel insights into understanding how astrocyte reactivity affects the cortical tau aggregation and cortical thinning in AD. Here, GFAP is linked to Alzheimer disease.